-COVID-19

Jennifer Hammond1, Carla Yunis1, Robert J Fountaine1

  • 1From Global Product Development, Pfizer, Collegeville, PA (J.H.); Global Product Development, Pfizer, Lake Mary (C.Y.), and Global Product Development, Pfizer, Tampa (J.M.R.) - both in Florida; Global Product Development, Pfizer, Groton, CT (R.J.F., H.S.); Global Product Development, Pfizer International Organization, Paris (G.L.); Pfizer, Chicago (A.M.B.); Global Product Development, Pfizer, Lake Forest, IL (W.Z., W.W.); Early Clinical Development, Pfizer, Cambridge, MA (M.L.B.); Medical and Safety, Pfizer Research and Development UK, Sandwich, United Kingdom (V.M.H.); Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases, Haskovo, Bulgaria (V.K.); and Global Product Development, Pfizer, New York (R.P.).

概括

在暴露后预防试验中,涅玛特里尔维尔-里托纳维尔并没有显著降低2019年新冠肺炎 (Covid-19) 症状感染的风险. 这项研究发现,与安慰剂相比,5天或10天的治疗方案没有显著的益处.